Clarkston Capital Partners LLC Purchases 50 Shares of Eli Lilly and Company $LLY

Clarkston Capital Partners LLC increased its holdings in Eli Lilly and Company (NYSE:LLY) by 0.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,050 shares of the company’s stock after buying an additional 50 shares during the period. Clarkston Capital Partners LLC’s holdings in Eli Lilly and Company were worth $7,834,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in LLY. Wealth Preservation Advisors LLC acquired a new position in Eli Lilly and Company in the first quarter valued at about $27,000. Sumitomo Mitsui Financial Group Inc. bought a new position in Eli Lilly and Company in the 2nd quarter valued at about $27,000. Financial Gravity Companies Inc. acquired a new position in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $31,000. Blume Capital Management Inc. lifted its holdings in shares of Eli Lilly and Company by 46.7% during the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after acquiring an additional 14 shares during the period. Finally, IMG Wealth Management Inc. acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter worth approximately $35,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Shares of LLY opened at $1,105.45 on Friday. The business has a 50-day moving average of $882.95 and a 200-day moving average of $797.01. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The company has a market capitalization of $1.05 trillion, a price-to-earnings ratio of 72.25, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,111.99.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same quarter in the prior year, the firm posted $1.18 EPS. The company’s revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Analysts Set New Price Targets

Several research analysts have commented on LLY shares. Daiwa Capital Markets boosted their price objective on shares of Eli Lilly and Company from $700.00 to $940.00 in a research report on Monday, November 10th. Hsbc Global Res raised Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Sanford C. Bernstein boosted their target price on Eli Lilly and Company from $1,100.00 to $1,300.00 and gave the stock an “outperform” rating in a research note on Monday. Finally, Morgan Stanley raised their price target on shares of Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the company an “overweight” rating in a research note on Monday. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $1,047.50.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.